Pharma Sector Secures Major GST Relief with Input Tax Credit on Free Samples and Expired Medicines The GST Council has approved input tax credit on physician samples and legally destroyed expired drugs starting financial year 2027-28, easing working capital pressures for drugmakers. Pharmaceutical manufacturers across India are set to receive substantial fiscal relief following key decisions reached at the 57th Goods and Services Tax Council meeting held in New Delhi on October 8. Announcing the policy measures after the session concluded, Finance Minister Nirmala Sitharaman detailed an upcoming framework that permits drug companies to claim input tax credit on goods distributed as promotional samples to healthcare professionals, as well as pharmaceutical inventories discarded due to expiry. The statutory updates modifying the current tax treatment are scheduled to take effect beginning in financial year 2027-28. Streamlined Refund Framework to Enhance Liquidity Within the pharmaceutical business model, circulating non-commercial physician samples and strictly disposing of time-sensitive medicinal batches are routine regulatory obligations. By approving recommendations to rationalize the credit mechanism and overhaul tax refund processing, the council intends to provide operational relief to pharmaceutical production hubs. The reform is projected to optimize working capital liquidity across production lines while bolstering competitiveness in export markets. Until now, the inability to claim credit on such write-offs added directly to procurement and manufacturing overheads, tying up crucial funds. Conditions Governing Eligibility for Credit Authorities have demarcated strict boundaries around when written-off goods qualify for input credits, clarifying that claims will be valid solely when destruction is mandatory under established healthcare laws. Assessing the regulatory landscape, Ashish Jain, Partner and Life Sciences & Healthcare Tax Leader at EY India, noted that the measures bring meaningful gains to companies developing vaccine batches, formulations, biologic products, diagnostics, and consumer health lines. These product categories routinely commit heavy outlays toward advanced factory infrastructure, ongoing trial distributions, and sensitive inventory life-cycle maintenance. Industry Perspective on Capital Goods and Services Deloitte India indirect tax leader Mahesh Jaising observed that the council's decision delivers a two-fold fiscal boost to domestic pharmaceutical firms. Removing accumulated taxes from expired inventory directly lightens balance-sheet carrying costs. Concurrently, incorporating input services and capital goods into refund calculations addresses a persistent operational friction point for the sector. Suresh Nair, an indirect tax partner handling consumer and health sciences at EY India, pointed out that recognizing input services and capital goods will significantly aid enterprises investing in new production units, specialized equipment, and export-driven capacity expansions. What this means for you The tax relief lowers operational overheads for pharmaceutical manufacturers and unlocks tied-up liquidity across their supply chains. • Operational Cash Flows: Permitting input credit on destroyed stock and doctor samples directly reduces locked-in working capital. Pharmaceutical facilities will retain higher liquid reserves to deploy into production and research activities. • Pricing and Overhead Dynamics: Lifting trapped tax burdens off discarded inventory mitigates unnecessary factory overheads. Over time, leaner operating expenses help keep essential healthcare products and therapies price-stable for end buyers. • Export Competitiveness: Factoring capital assets and services into refund calculations will sharpen the pricing edge of Indian drugmakers overseas. Exporters can recover duties incurred on cutting-edge machinery and facility upgrades without lengthy delays. • Clinical and Physician Engagement: Retaining credit on promotional medical samples allows enterprises to market newer formulations without penal tax penalties. Healthcare practitioners can continue receiving vital clinical trial samples and drug updates smoothly. Why this happened The GST Council instituted this reform to align tax statutes with the unique statutory and operational realities of pharmaceutical manufacturing. • Statutory Mandates: Healthcare laws make the destruction of expired drug batches strictly mandatory for public safety. Denying tax credits on legally mandated stock write-offs imposed an unfair financial penalty on compliant drugmakers. • Promotional Necessities: Distributing complimentary formulation samples to medical doctors is standard industry protocol to build clinical awareness. Barring tax credits on these non-revenue distributions had artificially elevated sales and marketing expenses. • Encouraging Capital Investment: Integrating service inputs and industrial machinery into refund formulas was a longstanding industry petition. The administration approved the change to incentivize companies modernizing their manufacturing infrastructure and upgrading plants. Questions & Answers 1. What major decision did the GST Council take regarding pharmaceutical companies? The council decided to allow input tax credit on free samples given to doctors and on expired medicines that are destroyed. 2. When will this new tax credit framework come into effect? These modifications to GST regulations and rules are scheduled to take effect from financial year 2027-28. 3. Can companies claim input tax credit on all destroyed inventory? No, input tax credit will only be permitted in instances where destruction of the goods is mandated under applicable law. 4. Which segments within the healthcare sector will benefit most from this move? Producers of formulations, vaccines, biological products, diagnostics, and consumer healthcare lines stand to gain significantly. https://trendkia.com/en/business/pharma-knpaniyon-ko-gst-men-bari-rahata-muphta-sainpala-aura-eksapayara-davaon-para-milega-taiksa-kredita-45562 TrendKia — Har trend, sabse pehle.